New appointment at DxS
This article was originally published in Scrip
Executive Summary
The UK personalised medicine company DxS has named Dr David Jackson vice-president of business development and licensing. He will be responsible for business development efforts for the companion diagnostics and technology licensing business units of DxS and will be based in the US. Dr Jackson was most recently executive vice-president at Response Genetics. Before that, he was president and chief operating officer at CryoFluor Therapeutics.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.